WO2025180383 - ANTI-TPBG/MUC1 ANTIBODIES AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2025/180383
Publication Date
04.09.2025
International Application No.
PCT/CN2025/079190
International Filing Date
26.02.2025
Title **
[English]
ANTI-TPBG/MUC1 ANTIBODIES AND USES THEREOF
[French]
ANTICORPS ANTI-TPBG/MUC1 ET UTILISATIONS ASSOCIÉES
Applicants **
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
Inventors
XU, Yangyang
ZHANG, Yifu
SHANG, Chengzhang
YANG, Yi
SHEN, Yuelei
Priority Data
PCT/CN2024/078555
26.02.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2911 | |
| EPO | Filing, Examination, Granting | 27502 | |
| Japan | Filing, Examination, Granting | 3019 | |
| South Korea | Filing, Examination, Granting | 3998 | |
| USA | Filing, Examination, Granting | 14140 |

Total:
51,570
Contact Us
Abstract[English]
Anti-TPBG/MUC1 antibodies and antibody drug conjugates derived therefrom, and the use thereof are provided.[French]
L'invention concerne des anticorps anti-TPBG/MUC1 et des conjugués anticorps-médicament dérivés de ceux-ci, ainsi que des utilisations associées.